Arcus Biosciences stock trades 16.8 percent below yearly high

Published on 09/24/2026 at 09:49 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Arcus Biosciences stock delivered USD 41 million in Q2 2026 revenue against USD 21.98 million consensus. New casdatifan data are scheduled for October 20, 2026.

Arcus Biosciences stock, biotechnology, casdatifan, kidney cancer data, investor event, NYSE, Illustration mit AI erstellt.

Arcus Biosciences stock (ISIN US03969F1093) stood at USD 26.39 on the NYSE on September 23, 2026, 16.8 percent below its 52-week high of USD 31.73. The company has scheduled a October 20, 2026 investor event centered on new casdatifan kidney cancer data, according to Business Wire.

Casdatifan takes center stage

The October 20 event will present ARC-20 data for casdatifan as a standalone treatment and in combinations across first-, second- and late-line clear cell renal cell carcinoma. The program is designed to support development of casdatifan as a backbone therapy across multiple stages of kidney cancer treatment, while the drug remains investigational.

The event matters because Arcus is concentrating resources on casdatifan after discontinuing several Phase 3 domvanalimab studies. Management described the shift during the Q2 2026 earnings call, with cash, cash equivalents and marketable securities of USD 775 million as of June 30, 2026, according to Motley Fool.

Revenue beat meets cash discipline

Arcus reported USD 41 million of revenue for Q2 2026, compared with a USD 21.98 million consensus estimate, while adjusted loss was USD 0.72 per share versus a USD 0.89 expected loss. The revenue beat was substantial, but the company remains loss-making as it funds late-stage clinical development, according to MarketBeat.

The financial profile creates a clear tradeoff. The USD 775 million liquidity position is expected to fund operations into at least the second half of 2028, yet Q2 net loss reached USD 91 million. Investors therefore have to weigh the runway against the clinical evidence needed to justify continued investment in casdatifan.

Stock remains below yearly peak

At USD 26.39 on September 23, 2026, Arcus Biosciences stock was down USD 0.48, or 1.79 percent, from the previous close of USD 26.87. The quote was 16.8 percent below the 52-week high of USD 31.73, leaving the October data event as the next dated checkpoint for the pipeline story.